Uyeki T. M., Hui D.S., Zambon M., Wentworth D.E., Monto A.S. 2022. Influenza. Lancet. 400 (10353), 693–706. https://doi.org/10.1016/S0140-6736(22)00982-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohmit S.E., Thompson M.G., Petrie J.G., Thaker S.N., Jackson M.L., Belongia E.A., Zimmerman R.K., Gaglani M., Lamerato L., Spencer S.M., Jackson L., Meece J.K., Nowalk M.P., Song J., Zervos M., Cheng P.Y., Rinaldo C.R., Clipper L., Shay D.K., Piedra P., Monto A.S. 2014. Influenza vaccine effectiveness in the 2011−2012 season: Protection against each circulating virus and the effect of prior vaccination on estimates. Clin. Infect. Dis. 58 (3), 319‒327. https://doi.org/10.1093/cid/cit736

Article  PubMed  Google Scholar 

Wei C.J., Crank M.C., Shiver J., Graham B.S., Mascola J.R., Nabel G.J. 2020. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discovery. 19 (6), 239–252. https://doi.org/10.1038/s4573-020-0066-8

Article  CAS  PubMed  Google Scholar 

Scorza F.B., Pardi N. 2018. New kids on the block: RNA-based influenza virus vaccines. Vaccines (Basel). 6 (2), 20. https://doi.org/10.3390/vaccines6020020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C., Maruggi G., Shan H., Li J. 2019. Advances in mRNA vaccines for infectious diseases. Front. Immunol. 10, 594. https://doi.org/10.3389/fimmu.2019.00594

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardi N., Hogan M.J., Porter F.W., Weissman D. 2018. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discovery. 7 (4), 261‒279. https://doi.org/10.1038/nrd.2017.243

Article  CAS  Google Scholar 

Vogel A.B., Kanevsky I., Che Y., Swanson K.A., Muik A., Vormehr M., Kranz L.M., Walzer K.C., Hein S., Güler A., Loschko J., Maddur M.S., Ota-Setlik A., Tompkins K., Cole J., Lui B.G., Ziegenhals T., Plaschke A., Eisel D., Dany S.C., Fesser S., Erbar S., Bates F., Schneider D., Jesionek B., Sänger B., Wallisch A.K., Feuchter Y., Junginger H., Krumm S.A., Heinen A.P., Adams-Quack P., Schlereth J., Schille S., Kröner C., de la Caridad Güimil Garcia R., Hiller T., Fischer L., Sellers R.S., Choudhary S., Gonzalez O., Vascotto F., Gutman M.R., Fontenot J.A., Hall-Ursone S., Brasky K., Griffor M.C., Han S., Su A.A.H., Lees J.A., Nedoma N.L., Mashalidis E.H., Sahasrabudhe P.V., Tan C.Y., Pavliakova D., Singh G., Fontes-Garfias C., Pride M., Scully I.L., Ciolino T., Obregon J., Gazi M., Carrion R. Jr., Alfson K.J., Kalina W.V., Kaushal D., Shi P.Y., Klamp T., Rosenbaum C., Kuhn A.N., Türeci Ö., Dormitzer P.R., Jansen K.U., Sahin U. 2021. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 592 (7853), 283–289. https://doi.org/10.1038/s41586-021-03275-y

Article  CAS  PubMed  Google Scholar 

Chan L., Alizadeh K., Alizadeh K., Fazel F., Kakish J.E., Karimi N., Knapp J.P., Mehrani Y., Minott J.A., Morovati S., Rghei A., Stegelmeier A.A., Vanderkamp S., Karimi K., Bridle B.W. 2021. Review of influenza virus vaccines: The qualitative nature of immune responses to infection and vaccination is a critical consideration. Vaccines (Basel). 9 (9) 979. https://doi.org/10.3390/vaccines9090979

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walsh E.E., Frenck R.W. Jr., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., Swanson K.A., Li P., Koury K., Kalina W., Cooper D., Fontes-Garfias C., Shi P.Y., Türeci Ö., Tompkins K.R., Lyke K.E., Raabe V., Dormitzer P.R., Jansen K.U., Şahin U., Gruber W.C. 2020. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383 (25), 2439‒2450. https://doi.org/10.1056/NEJMoa2027906

Article  CAS  PubMed  Google Scholar 

Teo S.P. 2022. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J. Pharm. Pract. 35 (6), 947‒951. https://doi.org/10.1177/08971900211009650

Article  PubMed  Google Scholar 

Freyn A.W., Pine M., Rosado V.C., Benz M., Muramatsu H., Beattie M., Tam Y.K., Krammer F., Palese P., Nachbagauer R., McMahon M., Pardi N. 2021. Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Mol. Ther. Methods Clin. Dev. 22, 84‒95. https://doi.org/10.1016/j.omtm.2021.06.003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mazunina E.P., Gushchin V.A., Kleymenov D.A., Siniavin A.E., Burtseva E.I., Shmarov M.M., Mukasheva E.A., Bykonia E.N., Kozlova S.R., Evgrafova E.A., Zolotar A.N., Shidlovskaya E.V., Kirillova E.S., Krepkaia A.S., Usachev E.V., Kuznetsova N.A., Ivanov I.A., Dmitriev S.E., Ivanov R.A., Logunov D.Y., Gintsburg A.L. 2024. Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response. Front. Immunol. 15, 1381508. https://doi.org/10.3389/fimmu.2024.1381508

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joe P.T., Christopoulou I., van Hoecke L., Schepens B., Ysenbaert T., Heirman C., Thielemans K., Saelens X., Aerts J.L. 2019. Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice. J. Transl. Med. 17 (1), 242. https://doi.org/10.1186/s12967-019-1991-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhuang X., Qi Y., Wang M., Yu N., Nan F., Zhang H., Tian M., Li C., Lu H., Jin N. 2020. mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice. Vaccines (Basel). 8 (1), 123. https://doi.org/10.3390/vaccines8010123

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kackos C.M., DeBeauchamp J., Davitt C.J.H., Lonzaric J., Sealy R.E., Hurwitz J.L., Samsa M.M., Webby R.J. 2023. Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection. NPJ Vaccines. 8 (1), 157. https://doi.org/10.1038/s41541-023-00752-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian Y., Deng Z., Chuai Z., Li C., Chang L., Sun F., Cao R., Yu H., Xiao R., Lu S., Xu Y., Yang P. 2024. A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge. Virology. 596, 110125. https://doi.org/10.1016/j.virol.2024.110125

Article  CAS  PubMed  Google Scholar 

Li Y., Wang X., Zeng X., Ren W., Liao P., Zhu B. 2023. Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice. mLife. 2 (3), 308‒316. https://doi.org/10.1002/mlf2.12085

Nitika, Wei J., Hui A.M. 2022. The delivery of mRNA vaccines for therapeutics. Life (Basel). 12 (8), 1254. https://doi.org/10.3390/life12081254

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramachandran S., Satapathy S.R., Dutta T. 2022. Delivery strategies for mRNA vaccines. Pharm. Med. 36 (1), 11–20. https://doi.org/10.1007/s40290-021-00417-5

Article  CAS  Google Scholar 

Buschmann M.D., Carrasco M.J., Alishetty S., Paige M., Alameh M.G., Weissman D. 2021. Nanomaterial delivery systems for mRNA vaccines. Vaccines (Basel). 9 (1), 65. https://doi.org/10.3390/vaccines9010065

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim B., Hosn R.R., Remba T., Yun D., Li N., Abraham W., Melo M.B., Cortes M., Li B., Zhang Y., Dong Y., Irvine D.J. 2023. Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines. J. Controlled Release. 353, 241‒253. https://doi.org/10.1016/j.jconrel.2022.11.022

Article  CAS  Google Scholar 

Tsilingiris D., Vallianou N.G., Karampela I., Liu J., Dalamaga M. 2022. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabol. Open. 13, 100159. https://doi.org/10.1016/j.metop.2021.100159

Article  CAS  PubMed  Google Scholar 

Wilczewska A.Z., Niemirowicz K., Markiewicz K.H., Car H. 2012. Nanoparticles as drug delivery systems. Pharmacol. Rep. 64 (5), 1020‒1037. https://doi.org/10.1016/s1734-1140(12)70901-5

Article  CAS  PubMed  Google Scholar 

Eygeris Y., Gupta M., Kim J., Sahay G. 2022. Chemistry of lipid nanoparticles for RNA delivery. Acc. Chem. Res. 55 (1), 2–12. https://doi.org/10.1021/acs.accounts.1c00544

Article  CAS  PubMed  Google Scholar 

Fraiman J., Erviti J., Jones M., Greenland S., Whelan P., Kaplan R.M., Doshi P. 2022. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 40 (40), 5798‒5805. https://doi.org/10.1016/j.vaccine.2022.08.036

Article  CAS  PubMed  PubMed Central